ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ODD ODDITY Tech Ltd.

Market Closed 10-23 16:00:00 EDT

22.65

-0.70

-3.00%

盘后22.65

+0.000.00%

19:53 EDT

High23.39	Low22.60	Vol461.20K
Open23.02	D1 Closing23.35	Amplitude3.40%
Mkt Cap1.04B	Tradable Cap647.47M	Total Shares46.12M
T/O10.56M	T/O Rate1.61%	Tradable Shares28.59M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ODD","market":"US","secType":"STK","nameCN":"ODDITY Tech Ltd.","latestPrice":22.65,"timestamp":1792785600000,"preClose":23.35,"halted":0,"volume":461201,"hourTrading":{"tag":"盘后","latestPrice":22.65,"preClose":22.65,"latestTime":"19:53 EDT","volume":12683,"amount":287271.05,"timestamp":1792799619062,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.029978586723768855,"floatShares":28586000,"shares":46124600,"eps":0.22,"marketStatus":"Market Closed","change":-0.7,"latestTime":"10-23 16:00:00 EDT","open":23.02,"high":23.39,"low":22.595,"amount":10557317.962126,"amplitude":0.034047,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.22,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1793001600000},"marketStatusCode":7,"adr":0,"listingDate":1689739200000,"exchange":"NASDAQ","adjPreClose":23.35,"preHourTrading":{"tag":"盘前","latestPrice":22.8402,"preClose":23.35,"latestTime":"09:25 EDT","volume":468,"amount":10846.721808,"timestamp":1792761900029,"change":-0.5098,"changeRate":-0.021833,"amplitude":0.11051},"postHourTrading":{"tag":"盘后","latestPrice":22.65,"preClose":22.65,"latestTime":"19:53 EDT","volume":12683,"amount":287271.05,"timestamp":1792799619062,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8847649153304522,"impliedVol":0.9266,"impliedVolPercentile":0.4781},"requestUrl":"/m/hq/s/ODD/tweets","defaultTab":"tweets","newsList":[{"id":"2676020664","title":"Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Stage in Phase II First-Line Gastric Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2676020664","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676020664?lang=en_us&edition=fundamental","pubTime":"2026-10-20 18:18","pubTimestamp":1792491480,"startTime":"0","endTime":"0","summary":"Expansion Stage to Compare Opamtistomig Plus Chemotherapy Head-to-Head With Tislelizumab Plus Chemotherapy in Previously Untreated DiseaseNANJING, China, Oct.  20, 2026 (GLOBE NEWSWIRE) -- Nanjing Lea","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/20/3384186/0/en/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-advances-to-expansion-stage-in-phase-ii-first-line-gastric-cancer-study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BITU","BRRR","COAL","IBIT","EZBC","BTCI","FBTC","BPI","BTRN","QBF","CBTA","CRC","BITB","ODD","BTCC","CBOY","BFJL","XHB","OC","SBIT","CBOA","BITX","HODL","DFII","CBXA","BTCO","BTF","BCCC","CBXO","CBOO","CBOJ","BTCL","BTCW","BFAP","BTC","PFS","YBTC","CPS","CBTY","MAXI","BITO","BITY","XBTY","BETH","CBTJ","HCC","BAGY","GBTC","ARKB","BITI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676568201","title":"Moomoo Extends Options Trading Hours* with Pre-Market and Post-Close Sessions","url":"https://stock-news.laohu8.com/highlight/detail?id=2676568201","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676568201?lang=en_us&edition=fundamental","pubTime":"2026-10-19 23:34","pubTimestamp":1792424040,"startTime":"0","endTime":"0","summary":"Expansion covers options on 25 stocks and five ETFs, providing investors with the flexibility to trade outside traditional market hoursJERSEY CITY, N.J., Oct.  19, 2026 (GLOBE NEWSWIRE) -- Moomoo, a l","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/19/3383687/0/en/moomoo-extends-options-trading-hours-with-pre-market-and-post-close-sessions.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","ODD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676368156","title":"Leads Biolabs' Opamtistomig and LBL-034 Featured in Six Abstracts at 2026 ESMO Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2676368156","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676368156?lang=en_us&edition=fundamental","pubTime":"2026-10-19 21:42","pubTimestamp":1792417320,"startTime":"0","endTime":"0","summary":"Three Studies Selected for Oral Presentation, Including a Late-Breaking Abstract; Data Highlight Durable Responses and Long-Term Survival Signals Across Immunologically Cold Tumors and Deep, Sustained","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/19/3383535/0/en/leads-biolabs-opamtistomig-and-lbl-034-featured-in-six-abstracts-at-2026-esmo-congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XAR","BETH","EMD","HODL","ARKB","CR","BTCO","BTC","CBTA","EZBC","XHB","MNRS","DEFI","XBTY","BRRR","YBTC","BFJL","BTCZ","BITY","BITI","QBF","BCCC","ODD","COAL","BTRN","ASH","PYZ","CBTO","CBXY","CBOA","CBOJ","OC","BITU","CRS","HCC","MAXI","CBXO","ORR","DFII","BITO","BTCW","CBXA","CBXJ","FBTC","BITX","BTCI","MSS","BTCL","CBTJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675563849","title":"Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2675563849","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675563849?lang=en_us&edition=fundamental","pubTime":"2026-10-16 12:47","pubTimestamp":1792126020,"startTime":"0","endTime":"0","summary":"Extending the Company's Immunologically Cold Tumor Strategy into Colorectal CancerNANJING, China , Oct.  16, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (\"Leads Biolabs\" or the \"Company,\"","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/16/3382247/0/en/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-enrolls-first-patient-in-phase-ib-ii-combination-trial-in-metastatic-colorectal-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTCC","BTF","CBXJ","BRRR","CBTJ","BITY","PROC","BTCI","BTC","BTRN","CBTY","OC","BITO","XHB","CBXO","BETH","BTCL","CBTO","GBTC","CBOO","MAXI","BITX","BTCW","EZBC","QBF","ODD","BAGY","CBOJ","DFII","CBXA","FBTC","HCC","IBIT","BTCZ","BITB","BITU","BFJL","CBOY","MSS","HODL","BTCO","YBTC","ARKB","CBOA","CBTA","COAL","BFAP","BETE","XBTY","SBIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675822435","title":"Analysts Have Conflicting Sentiments on These Consumer Goods Companies: Laureate Education (LAUR), ODDITY Tech Ltd. Class A (ODD) and Celsius Holdings (CELH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2675822435","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675822435?lang=en_us&edition=fundamental","pubTime":"2026-10-15 20:40","pubTimestamp":1792068057,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Consumer Goods sector with new ratings on Laureate Education (LAUR), ODDITY Tech Ltd. Class A (ODD) and...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-consumer-goods-companies-laureate-education-laur-oddity-tech-ltd-class-a-odd-and-celsius-holdings-celh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-consumer-goods-companies-laureate-education-laur-oddity-tech-ltd-class-a-odd-and-celsius-holdings-celh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4183","BREW","LU2362541513.USD","LU0278937759.USD","LU2362541273.HKD","LU2543165471.USD","CELT","LU2517655374.HKD","LU2517655291.USD","BK4585","LU2517655028.SGD","LAUR","BK4588","CELH","LU2065731478.USD","IE0009354923.USD","LU1989763005.USD","LU2211815571.USD","LU2362540622.SGD","LU1989773731.SGD","BK4204","LU2211817866.USD","ODD","BK4177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675835795","title":"ODDITY Tech (ODD) Seeks Dismissal of Securities Lawsuit Over Advertising Algorithm Disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2675835795","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675835795?lang=en_us&edition=fundamental","pubTime":"2026-10-15 17:40","pubTimestamp":1792057237,"startTime":"0","endTime":"0","summary":"ODDITY Tech Ltd. ($ODD) has asked a federal court to throw out a securities lawsuit accusing the consumer technology company and two of its executi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/oddity-tech-odd-seeks-dismissal-of-securities-lawsuit-over-advertising-algorithm-disclosures?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/oddity-tech-odd-seeks-dismissal-of-securities-lawsuit-over-advertising-algorithm-disclosures?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4183","ODD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674870312","title":"Discover Power Solutions International And 2 More Leading Growth Stocks With Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2674870312","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674870312?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:05","pubTimestamp":1791803140,"startTime":"0","endTime":"0","summary":"In the last week, the United States market has stayed flat, but it has seen a 15% increase over the past year with earnings projected to grow by 18% per annum in the coming years. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the company and potential alignment of interests with shareholders.","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6034000-choice1-card/1789283981127","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6034000-choice1-card/1789283981127"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-clov/clover-health-investments/news/discover-power-solutions-international-and-2-more-leading-gr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-clov/clover-health-investments/news/discover-power-solutions-international-and-2-more-leading-gr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE0009354923.USD","BK4182","ODD","BK4154","CLOV","PSIX","BK4183","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674284057","title":"Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2674284057","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674284057?lang=en_us&edition=fundamental","pubTime":"2026-10-12 09:47","pubTimestamp":1791769620,"startTime":"0","endTime":"0","summary":"Second FDA Fast Track Designation for Opamtistomig Underscores Its Potential in Immunologically Cold TumorsNANJING, China, Oct.  12, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Bi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/12/3378545/0/en/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-granted-fda-fast-track-designation-for-first-line-advanced-or-metastatic-biliary-tract-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BITY","BTCW","XHB","BEGS","BTCL","QBF","LABU","YBIT","OOQB","BRRR","BTC","BETH","DFII","ORR","BITB","BTGD","BTCI","COAL","CRPT","BAGY","GBTC","HODL","NCIQ","BTRN","BITX","SBIT","ARKY","DEFI","CBOJ","BETE","BTF","AEIS","BTFX","MAXI","ODD","OC","YBTC","IBIT","CBXY","MNRS","CBTJ","BTCZ","BFJL","CBXJ","MSBT","BCCC","HCC","STCE","FBTC","BFAP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673970740","title":"Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2673970740","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673970740?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:45","pubTimestamp":1791204300,"startTime":"0","endTime":"0","summary":"LOS ANGELES, CA, Oct.  05, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present at th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374561/0/en/immix-biopharma-to-participate-in-the-45th-annual-j-p-morgan-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2264538146.SGD","LU0158827781.USD","BK4183","LU1162221912.USD","LU2023251221.USD","LU0225283273.USD","LU1791710582.SGD","LU1989772923.USD","LU1074936037.SGD","IAI","LU2487616109.SGD","BK4127","HCSG","LU0528227936.USD","BK4516","LU1244550577.SGD","LU1244550494.USD","LU1668664300.SGD","BK4588","XBI","IE0009354923.USD","LU0106261372.USD","LU1988902786.USD","IE00BZ1G4Q59.USD","LU2028103732.USD","LU2111349929.HKD","LU1989772840.SGD","XLV","BK4137","LU0390134368.USD","LU0106831901.USD","IE00B3S45H60.SGD","LU1548497426.USD","BK4581","LU2089284900.SGD","LU0128526141.USD","LU0795875086.SGD","LU2089283258.USD","LU1244550221.USD","LU0795875169.SGD","LU2347655156.SGD","ODD","LU1064131342.USD","LABU","LU1363072403.SGD","LU1732800096.USD","KBWB","BK4534","LU1791710400.SGD","LU0006306889.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672787073","title":"Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2672787073","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672787073?lang=en_us&edition=fundamental","pubTime":"2026-10-01 05:15","pubTimestamp":1790802900,"startTime":"0","endTime":"0","summary":"– Financing includes leading U.S. biotechnology institutional investors and mutual funds –LOS ANGELES, CA, Sept.  30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3372434/0/en/immix-biopharma-announces-closing-of-125-million-underwritten-offering-of-common-stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","ODD","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671280201","title":"Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671280201","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671280201?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:00","pubTimestamp":1790766000,"startTime":"0","endTime":"0","summary":"BOSTON, Sept.  30, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3371756/0/en/tiziana-life-sciences-files-for-orphan-drug-designation-with-the-fda-for-intranasal-foralumab-for-the-treatment-of-multiple-system-atrophy-msa.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1585245621.USD","BK4533","BK4085","LU0950375773.USD","NERD","ESPO","LU1121112475.USD","BK4588","LU0426412945.USD","LU0154245756.USD","LU0823417653.USD","LU1923622291.USD","BK4577","LU0154245673.USD","HERO","LU2247934214.USD","LU0994945656.USD","BK4183","LU2506951875.HKD","LU2506952097.USD","IE0009354923.USD","LU1430594728.SGD","LU0823417737.USD","LU2211815571.USD","LU0006061336.USD","LU2125909759.SGD","LU1043141123.HKD","ODD","LU0640476718.USD","LU1815336091.USD","BK4585","LU0426417589.USD","MSA","EA","LU0728928796.USD","LU0757428866.USD","BNGE","LU0053671581.USD","BK4532","LU2506952170.USD","LU1280957306.USD","LU2125909916.SGD","LU1043141396.HKD","LABU","BK4143","LU2506951958.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671690216","title":"Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2671690216","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671690216?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:05","pubTimestamp":1790679900,"startTime":"0","endTime":"0","summary":"LOS ANGELES, Sept.  29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the prici","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/29/3370690/0/en/immix-biopharma-announces-pricing-of-125-million-underwritten-offering-of-common-stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","ODD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671321663","title":"Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2671321663","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671321663?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:00","pubTimestamp":1790679600,"startTime":"0","endTime":"0","summary":"– 100% (25/25) of new patients are either in complete response (CR) or MRD-negative (21/25 are in CR; remaining 4/25 are MRD-negative) – – To-date, all patients achieving MRD-negativity reached CR wit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/29/3370648/0/en/immix-biopharma-announces-89-complete-response-rate-at-interim-update-across-all-nexicart-2-patients-with-mrd-negativity-indicating-potential-to-reach-up-to-98-complete-response-ra.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","IE0009354923.USD","CR","BK4161","ODD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670281218","title":"Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition","url":"https://stock-news.laohu8.com/highlight/detail?id=2670281218","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670281218?lang=en_us&edition=fundamental","pubTime":"2026-09-28 14:49","pubTimestamp":1790578140,"startTime":"0","endTime":"0","summary":"NANJING, China, Sept.  28, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that opamtistomig (LBL-024), the Company’s p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/28/3369527/0/en/leads-biolabs-pd-l1-4-1bb-bispecific-antibody-opamtistomig-lbl-024-granted-orphan-drug-designation-in-japan-further-expanding-global-regulatory-recognition.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTCO","ODD","BTF","BAGY","BTCZ","MNRS","ARKB","HODL","MAXI","CBTJ","BITY","BTCC","BTC","BCCC","BRRR","CBXY","YBTC","BTRN","CBTO","CBOJ","EZBC","BFJL","OC","XHB","BITB","BTCI","CBOY","CBOA","CBTY","FBTC","BETH","QBF","BFAP","BITO","BITX","BPI","BITU","BTCL","IBIT","EC","GBTC","CBXA","CBOO","HCC","SBIT","XBTY","CBXJ","BTCW","COAL","CBXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669746621","title":"Court Grants Motion to Dismiss Oddity Tech (ODD) Securities Lawsuit, Finding Material Misstatements Were Not Adequately Pleaded","url":"https://stock-news.laohu8.com/highlight/detail?id=2669746621","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669746621?lang=en_us&edition=fundamental","pubTime":"2026-09-24 17:38","pubTimestamp":1790242680,"startTime":"0","endTime":"0","summary":"A federal judge has granted a motion to dismiss the Second Amended Complaint in a securities fraud lawsuit against Oddity Tech Ltd. ($ODD), conclud...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/court-grants-motion-to-dismiss-oddity-tech-odd-securities-lawsuit-finding-material-misstatements-were-not-adequately-pleaded?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/court-grants-motion-to-dismiss-oddity-tech-odd-securities-lawsuit-finding-material-misstatements-were-not-adequately-pleaded?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD","IE0009354923.USD","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667066394","title":"Goldman Sachs Sticks to Its Sell Rating for ODDITY Tech Ltd. Class A (ODD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667066394","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667066394?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:35","pubTimestamp":1789385736,"startTime":"0","endTime":"0","summary":"In a report released today, Bonnie Herzog from Goldman Sachs maintained a Sell rating on ODDITY Tech Ltd. Class A, with a price target of $9.00. Ac...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/goldman-sachs-sticks-to-its-sell-rating-for-oddity-tech-ltd-class-a-odd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/goldman-sachs-sticks-to-its-sell-rating-for-oddity-tech-ltd-class-a-odd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667284652","title":"WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2667284652","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667284652?lang=en_us&edition=fundamental","pubTime":"2026-09-14 17:59","pubTimestamp":1789379940,"startTime":"0","endTime":"0","summary":"NANJING, China, Sept.  14, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that updated Phase II data for opamtistomig ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/14/3360871/0/en/wclc-2026-leads-biolabs-opamtistomig-lbl-024-oral-presentation-demonstrates-robust-response-and-pfs-benefits-in-first-line-nsclc.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BITB","BETE","BFJL","DEFI","HCC","BFAP","CBTO","BITY","CBOA","XTN","BITI","CBXO","BTC","CBXA","BITO","CBOY","CBXJ","BRRR","BAGY","COAL","BTCW","BTF","L","DFII","ODD","BTCC","ALK","BETH","SBIT","CBXY","MNRS","BITU","CBTA","EZBC","YBTC","OC","BTCO","CBOJ","BTCI","CBOO","BTCZ","GBTC","XHB","BITX","BPI","BTCL","HODL","MAXI","BTRN","BCCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666570326","title":"ODDITY Tech Earnings Call: Growth Brands vs Ad Shock","url":"https://stock-news.laohu8.com/highlight/detail?id=2666570326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666570326?lang=en_us&edition=fundamental","pubTime":"2026-09-12 08:05","pubTimestamp":1789171503,"startTime":"0","endTime":"0","summary":"ODDITY Tech Ltd. Class A (($ODD)) has held its Q2 earnings call. Read on for the main highlights of the call. ODDITY Tech’s latest earnings call mi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oddity-tech-earnings-call-growth-brands-vs-ad-shock?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oddity-tech-earnings-call-growth-brands-vs-ad-shock?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666558990","title":"Oddity Tech Price Target Raised to $18.00/Share from $16.00 by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666558990","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666558990?lang=en_us&edition=fundamental","pubTime":"2026-09-10 05:39","pubTimestamp":1788989940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ODD/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","BK4183","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666558920","title":"Analysts’ Opinions Are Mixed on These Consumer Goods Stocks: Delfi (OtherPEFDF) and ODDITY Tech Ltd. Class A (ODD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666558920","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666558920?lang=en_us&edition=fundamental","pubTime":"2026-09-10 05:30","pubTimestamp":1788989407,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Consumer Goods sector with new ratings on Delfi (PEFDF) and ODDITY Tech Ltd. Class A (ODD). Delfi (PEFD...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-consumer-goods-stocks-delfi-otherpefdf-and-oddity-tech-ltd-class-a-odd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-consumer-goods-stocks-delfi-otherpefdf-and-oddity-tech-ltd-class-a-odd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4212","PEFDF","IE0009354923.USD","ODD","BK4183"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://oddity.com","stockEarnings":[{"period":"1week","weight":0.0098},{"period":"1month","weight":0.2703},{"period":"3month","weight":0.4765},{"period":"6month","weight":0.4103},{"period":"1year","weight":-0.5193},{"period":"ytd","weight":-0.4363}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0285},{"period":"6month","weight":0.0645},{"period":"1year","weight":0.1313},{"period":"ytd","weight":0.1145}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oddity Tech Ltd. operates as a consumer tech company that builds and scales digital-first brands to disrupt beauty and wellness industries. The company serves consumers worldwide through its AI-driven online platform, deploying data science to identify consumer needs, and developing solutions in the form of beauty and wellness products. It owns IL MAKIAGE and SpoiledChild brands. The company was incorporated in 2013 and is headquartered in Tel Aviv, Israel with additional office in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.053143},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.207461},{"month":3,"riseRate":0.666667,"avgChangeRate":0.025113},{"month":4,"riseRate":0.666667,"avgChangeRate":0.079804},{"month":5,"riseRate":0.666667,"avgChangeRate":0.086142},{"month":6,"riseRate":1,"avgChangeRate":0.075724},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.034719},{"month":8,"riseRate":0.25,"avgChangeRate":-0.108719},{"month":9,"riseRate":0.75,"avgChangeRate":0.02737},{"month":10,"riseRate":0.25,"avgChangeRate":-0.051974},{"month":11,"riseRate":0.666667,"avgChangeRate":0.166696},{"month":12,"riseRate":0.333333,"avgChangeRate":0.066185}],"exchange":"NASDAQ","name":"ODDITY Tech Ltd.","nameEN":"ODDITY Tech Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ODDITY Tech Ltd.(ODD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ODDITY Tech Ltd.,ODD,ODDITY Tech Ltd.股票,ODDITY Tech Ltd.股票老虎,ODDITY Tech Ltd.股票老虎国际,ODDITY Tech Ltd.行情,ODDITY Tech Ltd.股票行情,ODDITY Tech Ltd.股价,ODDITY Tech Ltd.股市,ODDITY Tech Ltd.股票价格,ODDITY Tech Ltd.股票交易,ODDITY Tech Ltd.股票购买,ODDITY Tech Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ODDITY Tech Ltd.(ODD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}